JP2017514801A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514801A5
JP2017514801A5 JP2016561311A JP2016561311A JP2017514801A5 JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5 JP 2016561311 A JP2016561311 A JP 2016561311A JP 2016561311 A JP2016561311 A JP 2016561311A JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5
Authority
JP
Japan
Prior art keywords
xaa
chem
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514801A (ja
JP6768515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057442 external-priority patent/WO2015155151A1/en
Publication of JP2017514801A publication Critical patent/JP2017514801A/ja
Publication of JP2017514801A5 publication Critical patent/JP2017514801A5/ja
Application granted granted Critical
Publication of JP6768515B2 publication Critical patent/JP6768515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561311A 2014-04-07 2015-04-07 二重アシル化glp−1化合物 Active JP6768515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163697.7 2014-04-07
EP14163697 2014-04-07
PCT/EP2015/057442 WO2015155151A1 (en) 2014-04-07 2015-04-07 Double-acylated glp-1 compounds

Publications (3)

Publication Number Publication Date
JP2017514801A JP2017514801A (ja) 2017-06-08
JP2017514801A5 true JP2017514801A5 (cg-RX-API-DMAC7.html) 2018-05-10
JP6768515B2 JP6768515B2 (ja) 2020-10-14

Family

ID=50434120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561311A Active JP6768515B2 (ja) 2014-04-07 2015-04-07 二重アシル化glp−1化合物

Country Status (6)

Country Link
US (1) US10689429B2 (cg-RX-API-DMAC7.html)
EP (1) EP3129041B1 (cg-RX-API-DMAC7.html)
JP (1) JP6768515B2 (cg-RX-API-DMAC7.html)
CN (1) CN106132985B (cg-RX-API-DMAC7.html)
ES (1) ES2741507T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015155151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP7053480B2 (ja) 2016-03-03 2022-04-12 ノヴォ ノルディスク アー/エス Glp-1誘導体及びその使用
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
RS64643B1 (sr) 2018-02-02 2023-10-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
BR112021006823A2 (pt) 2018-10-11 2021-07-27 Intarcia Therapeutics, Inc. polipeptídeos análogos de amilina humana e métodos de uso
CN111378027B (zh) * 2018-12-29 2022-04-15 万新医药科技(苏州)有限公司 一种索玛鲁肽前体的制备方法
BR112022002189A2 (pt) * 2019-09-02 2022-04-26 Novo Nordisk As Processo de produção de um comprimido, e, comprimido
WO2021089678A1 (en) 2019-11-06 2021-05-14 Novo Nordisk A/S Glp-1 receptor agonists in dementia
US20220395559A1 (en) 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
JP2023542867A (ja) * 2020-09-11 2023-10-12 グリンプス バイオ, インコーポレイテッド 疾患の検出/診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
PL202367B1 (pl) 1998-12-07 2009-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków
JP2003516322A (ja) 1999-11-12 2003-05-13 ノボ ノルディスク アクティーゼルスカブ ベータ細胞変性抑制のためのglp−1アゴニストの使用
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US7291594B2 (en) 2002-10-11 2007-11-06 Sanwa Kagaku Kenkyusho Co., Ltd. GLP-1 derivative and preparation thereof absorbable via mucous membrane
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN102686607B (zh) * 2009-12-16 2014-10-29 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US9006178B2 (en) * 2010-11-09 2015-04-14 Novo Nordisk A/S Double-acylated GLP-1 derivatives with a linker
EP2665470A1 (en) * 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 particles and compositions
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
JP6126097B2 (ja) * 2011-09-06 2017-05-10 ノヴォ ノルディスク アー/エス Glp−1誘導体
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013167455A1 (en) * 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
HK1217443A1 (zh) * 2013-01-29 2017-01-13 奥莎迪药品管理有限公司 用於糖尿病的口服治疗的药物组合物

Similar Documents

Publication Publication Date Title
JP2017514801A5 (cg-RX-API-DMAC7.html)
JP2014529629A5 (cg-RX-API-DMAC7.html)
JP2013543853A5 (cg-RX-API-DMAC7.html)
JP2014501712A5 (cg-RX-API-DMAC7.html)
JP2015517478A5 (cg-RX-API-DMAC7.html)
JP2015517477A5 (cg-RX-API-DMAC7.html)
JP2010538049A5 (cg-RX-API-DMAC7.html)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
TWI362392B (en) Acylated glp-1 compounds
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP5755398B2 (ja) 伸長されたglp−1化合物
JP2008533105A5 (cg-RX-API-DMAC7.html)
CN104519902B (zh) 双酰化glp‑1衍生物
JP2018505146A5 (cg-RX-API-DMAC7.html)
JP2012529463A5 (cg-RX-API-DMAC7.html)
JP2010529004A5 (cg-RX-API-DMAC7.html)
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2012506402A5 (cg-RX-API-DMAC7.html)
JP2005528337A5 (cg-RX-API-DMAC7.html)
JP2024059696A (ja) 5.8~8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液
NZ597554A (en) Selective glucagon-like-peptide-2 (glp-2) analogues
JP2017528419A5 (cg-RX-API-DMAC7.html)
JP2016531110A5 (cg-RX-API-DMAC7.html)
JP2017508741A5 (cg-RX-API-DMAC7.html)
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита